NVE Ephedra AERs Total 40; Yellow Jacket Distribution Halted
This article was originally published in The Tan Sheet
Executive Summary
NVE Pharmaceuticals has received only 40 adverse event reports related to its ephedra-containing dietary supplements, the firm tells Sen. Richard Durbin (D-Ill.) in an Oct. 21 letter
You may also be interested in...
NVE Offers Ephedra Study Funds; Metabolife Backs Mandatory Health Reports
NVE Pharmaceuticals will provide funding for "NIH or another appropriate government body to independently study the long-term safety of ephedra," the Newton, N.J.-based firm's President Robert Occhifinto testified at a July 23 Capitol Hill hearing
Mandatory AE Information Requirements Needed For CAERS Filings – AHPA
Adverse event reports should be required to contain certain information before being filed in the CFSAN Adverse Events Reporting System (CAERS), AHPA says in an Oct. 21 letter to the agency
Ephedra Weight-Loss Claims “Inappropriate,” FDA’s Crawford Says
Weight-loss and energy enhancement claims are "inappropriate" for ephedra-containing products, FDA Acting Commissioner Lester Crawford, PhD, said during an Oct. 8 Senate subcommittee hearing